PowerPoint - Imperial College Faculty of Medicine

P&R landscape: France
Products will be awarded an ASMR and an SMR rating; ASMR 4 (parity) or ASMR 5
(EU reference pricing for product) would mean no price premium vs existing
products.
Decision-making process
ASMR decision criteria
Key trends
• SMR rating is based on
severity of the disease:
• major
• important
• moderate
• minor
• insufficient to justify
reimbursement
• ASMR (incremental benefit
vs SOC) is rated between 1
and 5:
• major (1)
• important (2)
• moderate (3)
• minor (4)
• none (5)
1. Innovative product of
significant therapeutic benefit
2. Product of therapeutic benefit
in terms of efficacy and/or
reduction in side-effect profile
3. Existing product where
equivalent pharmaceuticals
exist; moderate improvement
in terms of efficacy and/or
reduction in side-effect profile
4. Minor improvement in terms of
efficacy and/or utility
5. No improvement but still
granted recommendations to
be listed
• ASMR ratings are getting lower
• SMR ratings are increasingly
being used to deny or restrict
reimbursement
• Importance of incremental
clinical benefit (better efficacy
or better safety profile, as
evidenced in relevant clinical
trials) will increase
• Innovative technologies will
require pharmacoeconomic
studies showing that they
provide cost-savings and
improve disease management
• Patient stratification is
becoming increasingly
important to limit budget
impact
Page 7